Media about us

• Corneal inlay for presbyopia shows promise without added visual problems in pseudophakes

  02 July 2015 Lynda Charters; Ralph Chu, MD / Ophthalmology Times

  

  Initial results with an investigational device for correcting presbyopia (Raindrop Near Vision Inlay, Revision Optics) are promising. The device improves near visual performance without added visual disturbance in pseudophakic patients.

• NovaMedica to develop up to 15 nano-drugs by 2020

  29 June 2015 Interfax. Russia & CIS Health & Pharmaceuticals

  

  LLC NovaMedica (Moscow) is planning to intensify research work to develop a portfolio of its own pharmaceutical products with the use of nano-technology. It is going to develop up to 15 innovative drugs within the coming seven years, most of which will be based on nano-technologies, the company said in a report.

• Celtaxsys $40.00 million Fundraising. William P Reddick Submitted Jun 10 SEC Form

  17 June 2015 Octafinance.com

  

  Celtaxsys, Inc., Corporation just released form D for $40.00 million equity financing. This is a new filing. Celtaxsys was able to sell $21.63 million so far. That is 54.07% of the financing round. The total offering amount was $40.00 million. The fundraising form was filled on 2015-06-10. The reason for the financing was: unspecified. The fundraising still has about $18.37 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

• Tobira Finishes Patient Enrollment for NASH Study

  16 June 2015 Leonor Mateus Ferreira / Hepatitis News Today

  

  Tobira Therapeutics, Inc. has finished recruiting patients for its phase 2b CENTAURstudy, which was designed to evaluate a therapy called cenicriviroc (CVC) in patients who suffer from non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company, which is focused on developing and commercializing therapeutic options to treat liver and inflammatory conditions, announced enrollment completion in a press release.

• New System to Detect Patient's Antibiotic Resistance to Take Just 30 Minutes

  16 June 2015 Drug Discovery & Development

  

  A new device being developed by medical experts will transform the time it takes to detect antibiotic resistance in patients from several days to just half an hour.

• Domain finds unmet need in CF

  15 June 2015 Steve Edelson / BioCentury

  

  Domain Associates has decided the best way to play the cystic fibrosis space is to find a molecule that can be combined with the ever-increasing number of cocktails emerging from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). To do so, Domain led a $40 million series D round for Celtaxsys Inc. last week, marking its first investment in CF.

• Suprachoroidal injection of triamcinolone acetonide for uveitis proves promising

  11 June 2015 Nancy Groves / Ophthalmology Times

  

  Patients with noninfectious uveitis who were treated with a single suprachoroidal injection of triamcinolone acetonide in a 6-month phase I/II clinical trial exhibited improvements in best-corrected visual acuity (BCVA), said investigator Debra A. Goldstein, MD.

• NovaMedica To Market Ferring’s IBD Therapies in Russia

  04 June 2015 Leonor Mateus Ferreira / IDB News Today

  

  The Russian pharmaceutical company NovaMedica and the Swiss biopharmaceutical company Ferring Pharmaceuticals have established a partnership to bring novel gastroenterological drug treatments for inflammatory bowel disease (IBD) to Russia. The two companies announced the signing of an agreement for commercializing a product line of treatments for ulcerative colitis, Crohn’s disease and bleeding fromesophageal varicose.

• NovaMedica and Ferring Pharmaceuticals Bring Innovative Gastroenterological Products From Switzerland to Russia

  04 June 2015 Yahoo! Finance

  

  NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.

• NovaMedica to market Ferring’s innovative GI products in Russia

  03 June 2015 The PharmaLetter

  

  Privately-held Switzerland-headquartered Ferring Pharmaceuticals has signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.